Genomic landscape, immune characteristics and prognostic mutation signature of cervical cancer in China

Abstract

Purpose This study aimed to analyse the genomic alteration profiles and immune characteristics of a cohort of Chinese cervical cancer patients to understand why certain patients benefited from molecular targeted therapies and immunotherapy as well as their prognostic significance. Methods PD-L1 expression and clinicopathological information were obtained from 98 cervical cancer patients. Differences in PD-L1 expression and gene mutations between squamous cell carcinoma (SCC) and adenocarcinoma (AC) were analysed by the chi-square test or Fisher's exact test. Differences in gene mutations between our cohort and The Cancer Genome Atlas (TCGA) cohort were tested by Fisher's exact test. Logistic regression was used to analyse factors influencing TMB-high. Results Positive PD-L1 expression was significantly higher in cervical SCC than in cervical AC (87% vs. 39%, p < 0.001). Frequently mutated genes in cervical cancer included the PIK3CA, KMT2D, and KMT2C genes, among others. PIK3CA gene mutation rates were significantly higher in SCC than in AC (p = 0.004). The TERT gene mutation rate was significantly higher in our cohort than in the TCGA cohort (12% vs. 1%, p < 0.001). The independent predictors of high TMB were KMT2C and LRP1B gene mutations (p < 0.05). We also found that PTEN mutations were associated with worse survival (median PFS, 12.16 vs. 21.75 months, p = 0.0024). Conclusion Cervical SCC and AC have different molecular profiles and immune characteristics, suggesting that targeted treatments for SCC and AC patients may improve clinical outcomes. KMT2C and LRP1B gene mutations are independent predictors of TMB-high status in cervical cancer. We also proposed the prognostic value of PTEN mutations.

Preclinical investigation of patient-derived cervical cancer organoids for precision medicine

“…We identified the specific genes through gene profiling analysis of the organoids and patient sample tissues. The KMT2C gene is the third-most frequent gene mutation in cervical cancer and is also associated with a high tumor mutational burden [ 42 ]. Our results suggest that the mutated KMT2C gene in all carcinoma types of cervical cancer has the potential to be a predictor of targeted treatment response and prognosis.…”

Angiogenesis-related lncRNAs index: A predictor for CESC prognosis, immunotherapy efficacy, and chemosensitivity

“…However, the efficacy of treatment with ICIs in CESC patients is limited, with response rates to ICIs ranging from 10% to 25% 77 . Also, the efficacy of this treatment strategy varies from person to person with significant individual differences 78 . We should examine how immune checkpoint genes are expressed in our samples and possibly screen for biomarkers that can be used to predict treatment efficacy in order to determine which patients would better benefit from ICIs.…”

Somatic KMT2D loss-of-function mutations in lung squamous cell carcinoma: a single-center cohort study

“…In addition to its tumor-suppressing candidates’ genes in various tumors, the KMT2D mutations have been found to be closely associated with the development of squamous cell carcinomas, such as head and neck squamous cell carcinoma, ESCC, cutaneous squamous cell carcinoma, cervical squamous cell carcinoma, and LUSC ( 38 - 42 ). The KMT2D acts as a tumor repressor since KMT2D loss of function modestly increased cell proliferation and colony formation in one disrupted KMT2D study.…”